Exenatide - Intarcia Therapeutics

Drug Profile

Exenatide - Intarcia Therapeutics

Alternative Names: Exenatide in DUROS®; Exenatide intravenous - Intarcia Therapeutics; Exenatide subcutaneous implant - Intarcia Therapeutics; Exendin-4; ITCA-650

Latest Information Update: 19 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intarcia Therapeutics
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Preregistration Type 2 diabetes mellitus

Most Recent Events

  • 19 Feb 2018 NCT01785771 (triggered from news on Intarcia) - Added recruitment termination info
  • 30 Jan 2018 Intarcia Therapeutics terminates enrolment in the phase III FREEDOM-1 HBL trial for Type-2 diabetes mellitus (adjunctive treatment) in USA (NCT01785771)
  • 01 Oct 2017 Intarcia Therapeutics completes a phase IIIb trial for Type-2 diabetes mellitus (Adjunctive treatment) in USA (NCT02638805)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top